ICLR
ICONCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
The best near-term bull read is that the core franchise may be intact despite the accounting failure: management said there was no customer, operational, or cash-flow impact, the quantified overstatement was below the prior 2% ceiling, and the stock's April 29 relief move suggests investors were positioned for worse.
Posture
Mixed
Lead driver
Value
What changed
Next scheduled catalyst: earnings 2026-07-21 · AMC.
What can break
Form 20-F has not yet been filed; management only guided to completion in the coming weeks.
Momentum
81
Value
67
Sentiment
9
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $108.00 · Bull $125.00 · Bear $85.00
Earnings
2026-07-21 · AMC
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-29 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $183.60
Why
Momentum81 · Δ7d -4.2
Value67 · Δ7d -0.3
Sentiment9 · Δ7d -2.2
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Value · See fundamentals
Momentum
81
26% active weight
Current posture
7d trendFlat
Δ7d
-4.2
Δ21d
-12.9
Value
67
39% active weight
Current posture
7d trendFlat
Δ7d
-0.3
Δ21d
+0.2
Sentiment
9
34% active weight
Current posture
7d trendSoftening
Δ7d
-2.2
Δ21d
-1.5
Why this grade
Composite grade C. Momentum 81.1 / Value 67.0 / Sentiment 8.8
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$13.02B
Beta
1.27
Shares Out
76.57M
P/E (TTM)
26.7
P/S (TTM)
1.86
P/FCF (TTM)
15.65
Rev YoY
+2.5%
EPS YoY
-46.2%
Gross Margin
+21.7%
Op Margin
+10.0%
Net Debt
$2.91B
Current Ratio
1.10
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology